Cancer of the corpus uteri

International Journal of Gynecology and Obstetrics

Volumn 131, Issue , 2015, Pages S96-S104

  Amant, Frédéric ^a   Mirza, Mansoor Raza ^b   Koskas, Martin ^c   Creutzberg, Carien L ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b University of Copenhagen   (Denmark)

^c BICHAT HOSPITAL   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GESTAGEN;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ANATOMY; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; DISTANT METASTASIS; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INOPERABLE CANCER; LAPAROSCOPICALLY ASSISTED VAGINAL HYSTERECTOMY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; PATIENT COUNSELING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADICAL HYSTERECTOMY; SALPINGOOOPHORECTOMY; SURGICAL APPROACH; SURGICAL TECHNIQUE; UTERUS CANCER; VAGINAL HYSTERECTOMY; WORLD HEALTH ORGANIZATION; FEMALE; MASS SCREENING; PATHOLOGY; PROCEDURES; UTERINE NEOPLASMS;

FEMALE; HUMANS; MASS SCREENING; NEOPLASM STAGING; UTERINE NEOPLASMS;

EID: 84944065830     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1016/j.ijgo.2015.06.005     Document Type: Article

References (110)

1. I. Winer, Q.F. Ahmed, I. Mert, S. Bandyopadhyay, M. Cote, A.R. Munkarah, and et al. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence? Int J Gynecol Pathol 34 1 2015 47 56
2. P. Aristizabal, O. Graesslin, E. Barranger, F. Clavel-Chapelon, B. Haddad, D. Luton, and et al. A suggested modification to FIGO stage I endometrial cancer Gynecol Oncol 133 2 2014 192 196
3. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 1 2015 5 29
4. C.M. Friedenreich, H.K. Neilson, and B.M. Lynch State of the epidemiological evidence on physical activity and cancer prevention Eur J Cancer 46 14 2010 2593 2604
5. A.E. Cust Physical activity and gynecologic cancer prevention Recent Results Cancer Res 186 2011 159 185
6. N.S. Nevadunsky, A. Van Arsdale, H.D. Strickler, A. Moadel, G. Kaur, J. Levitt, and et al. Obesity and age at diagnosis of endometrial cancer Obstet Gynecol 124 2 Pt 1 2014 300 306
7. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, and et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 6 2013 1374 1403
8. E. Weiderpass, J. Antoine, F.I. Bray, J.K. Oh, and M. Arbyn Trends in corpus uteri cancer mortality in member states of the European Union Eur J Cancer 50 9 2014 1675 1684
9. P. Wartko, M.E. Sherman, H.P. Yang, A.S. Felix, L.A. Brinton, and B. Trabert Recent changes in endometrial cancer trends among menopausal-age U.S. women Cancer Epidemiol 37 4 2013 374 377
10. R.J. Kurman, P.F. Kaminski, and H.J. Norris The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients Cancer 56 2 1985 403 412
11. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 9484 2005 491 505
12. I. Jacobs, A. Gentry-Maharaj, M. Burnell, R. Manchanda, N. Singh, A. Sharma, and et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women. A case-control study within the UKCTOCS cohort Lancet Oncol 12 1 2011 38 48
13. R.A. Smith, V. Cokkinides, and O.W. Brawley Cancer screening in the United States, 2009. A review of current American Cancer Society guidelines and issues in cancer screening CA Cancer J Clin 59 1 2009 27 41
14. B. Karlsson, S. Granberg, M. Wikland, P. Ylostalo, K. Torvid, K. Marsal, and et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding- A Nordic multicenter study Am J Obstet Gynecol 172 5 1995 1488 1494
15. H. Ugaki, T. Kimura, T. Miyatake, Y. Ueda, K. Yoshino, S. Matsuzaki, and et al. Intraoperative frozen section assessment of myometrial invasion and histology of endometrial cancer using the revised FIGO staging system Int J Gynecol Cancer 21 7 2011 1180 1184
16. T.J. Cade, M.A. Quinn, O.M. McNally, D. Neesham, J. Pyman, and A. Dobrotwir Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer. is radiological staging sufficient for planning conservative treatment? Int J Gynecol Cancer 20 7 2010 1166 1169
17. E. Ozturk, E. Dikensoy, O. Balat, M.G. Ugur, and A. Aydin Intraoperative frozen section is essential for assessment of myometrial invasion but not for histologic grade confirmation in endometrial cancer. A ten-year experience Arch Gynecol Obstet 285 5 2012 1415 1419
18. A. DelMaschio, A. Vanzulli, S. Sironi, D. Spagnolo, C. Belloni, P. Garancini, and et al. Estimating the depth of myometrial involvement by endometrial carcinoma: efficacy of transvaginal sonography vs MR imaging AJR Am J Roentgenol 160 3 1993 533 538
19. E. Epstein, and L. Blomqvist Imaging in endometrial cancer Best Pract Res Clin Obstet Gynaecol 28 5 2014 721 739
20. J.L. Walker, M.R. Piedmonte, N.M. Spirtos, S.M. Eisenkop, J.B. Schlaerth, R.S. Mannel, and et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer. Gynecol Oncol Group Study LAP2 J Clin Oncol 27 32 2009 5331 5336
21. M.J. Mourits, C.B. Bijen, H.J. Arts, H.G. ter Brugge, R. van der Sijde, L. Paulsen, and et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer. A randomised trial Lancet Oncol 11 8 2010 763 771
22. A. Obermair, M. Janda, J. Baker, S. Kondalsamy-Chennakesavan, A. Brand, R. Hogg, and et al. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial Eur J Cancer 48 8 2012 1147 1153
23. K. Galaal, A. Bryant, A.D. Fisher, M. Al-Khaduri, F. Kew, and A.D. Lopes Laparoscopy versus laparotomy for the management of early stage endometrial cancer Cochrane Database Syst Rev 9 2012 CD006655
24. J.L. Walker, M.R. Piedmonte, N.M. Spirtos, S.M. Eisenkop, J.B. Schlaerth, R.S. Mannel, and et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer. Gynecologic Oncology Group LAP2 Study J Clin Oncol 30 7 2012 695 700
25. M.Q. Bernardini, L.T. Gien, H. Tipping, J. Murphy, and B.P. Rosen Surgical outcome of robotic surgery in morbidly obese patient with endometrial cancer compared to laparotomy Int J Gynecol Cancer 22 1 2012 76 81
26. J. Cardenas-Goicoechea, A. Shepherd, M. Momeni, J. Mandeli, L. Chuang, H. Gretz, and et al. Survival analysis of robotic versus traditional laparoscopic surgical staging for endometrial cancer Am J Obstet Gynecol 210 2 2014 160.e1 160.e111
27. J.D. Wright, W.M. Burke, E.T. Wilde, S.N. Lewin, A.S. Charles, J.H. Kim, and et al. Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer J Clin Oncol 30 8 2012 783 791
28. M.E. Randall, V.L. Filiaci, H. Muss, N.M. Spirtos, R.S. Mannel, J. Fowler, and et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma. A Gynecol Oncol Group Study J Clin Oncol 24 1 2006 36 44
29. J.K. Chan, A.E. Sherman, D.S. Kapp, R. Zhang, K.E. Osann, L. Maxwell, and et al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer J Clin Oncol 29 7 2011 832 838
30. P.Y. Roland, F.J. Kelly, C.Y. Kulwicki, P. Blitzer, M. Curcio, and J.W. Orr Jr The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment Gynecol Oncol 93 1 2004 125 130
31. L.M. Elit, E.M. O'Leary, G.R. Pond, and H.Y. Seow Impact of wait times on survival for women with uterine cancer J Clin Oncol 32 1 2014 27 33
32. K. Matsuo, N.R. Opper, M.A. Ciccone, J. Garcia, K.E. Tierney, T. Baba, and et al. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer. association between tumor characteristics and survival outcome Obstet Gynecol 125 2 2015 424 433
33. L.C. Kilgore, E.E. Partridge, R.D. Alvarez, J.M. Austin, H.M. Shingleton, F. Noojin III, and et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling Gynecol Oncol 56 1 1995 29 33
34. D.M. Larson, S.K. Broste, and B.R. Krawisz Surgery without radiotherapy for primary treatment of endometrial cancer Obstet Gynecol 91 3 1998 355 359
35. J.M. Cragun, L.J. Havrilesky, B. Calingaert, I. Synan, A.A. Secord, J.T. Soper, and et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer J Clin Oncol 23 16 2005 3668 3675
36. ASTEC Study Group, H. Kitchener, A.M. Swart, Q. Qian, C. Amos, and M.K. Parmar Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study Lancet 373 9658 2009 125 136
37. P. Benedetti Panici, S. Basile, F. Maneschi, A. Alberto Lissoni, M. Signorelli, G. Scambia, and et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial J Natl Cancer Inst 100 23 2008 1707 1716
38. J.G. Aalders, and G. Thomas Endometrial cancer-revisiting the importance of pelvic and para aortic lymph nodes Gynecol Oncol 104 1 2007 222 231
39. Y. Todo, H. Kato, M. Kaneuchi, H. Watari, M. Takeda, and N. Sakuragi Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis Lancet 375 9721 2010 1165 1172
40. H.K. Poulsen, M. Jacobsen, K. Bertelsen, K. Andersen, S. Ahrons, J. Bock, and et al. Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low risk cases Int J Gynecol Cancer 6 1 1996 38 43
41. J. Aalders, V. Abeler, P. Kolstad, and M. Onsrud Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients Obstet Gynecol 56 4 1980 419 427
42. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, C.C. Warlam-Rodenhuis, and et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma Lancet 355 9213 2000 1404 1411
43. H.M. Keys, J.A. Roberts, V.L. Brunetto, R.J. Zaino, N.M. Spirtos, J.D. Bloss, and et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 3 2004 744 751
44. P. Blake, A.M. Swart, J. Orton, H. Kitchener, T. Whelan, H. Lukka, and et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis Lancet 373 9658 2009 137 146
45. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, C.C. Warlam-Rodenhuis, and et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial Gynecol Oncol 89 2 2003 201 209
46. R.A. Nout, V.T. Smit, H. Putter, I.M. Jurgenliemk-Schulz, J.J. Jobsen, L.C. Lutgens, and et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Lancet 375 9717 2010 816 823
47. R.A. Nout, H. Putter, I.M. Jurgenliemk-Schulz, J.J. Jobsen, L.C. Lutgens, E.M. van der Steen-Banasik, and et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial J Clin Oncol 27 21 2009 3547 3556
48. G. Ortoft, E.S. Hansen, and K. Bertelsen Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study Int J Gynecol Cancer 23 8 2013 1429 1437
49. M. Kunneman, A.H. Pieterse, A.M. Stiggelbout, R.A. Nout, M. Kamps, L.C. Lutgens, and et al. Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians Br J Cancer 111 4 2014 674 679
50. T. Hogberg, M. Signorelli, C.F. de Oliveira, R. Fossati, A.A. Lissoni, B. Sorbe, and et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies Eur J Cancer 46 13 2010 2422 2431
51. N. Susumu, S. Sagae, Y. Udagawa, K. Niwa, H. Kuramoto, S. Satoh, and et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer. A Japanese Gynecol Oncol Group study Gynecol Oncol 108 1 2008 226 233
52. R. Maggi, A. Lissoni, F. Spina, M. Melpignano, P. Zola, G. Favalli, and et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial Br J Cancer 95 3 2006 266 271
53. D.S. McMeekin, V.L. Filiaci, C. Aghajanian, J. Cho, J.W. Kim, P.A. DiSilvestro, and et al. A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial (Abstract) Presented at: SGO 45th Annual Meeting on Women's Cancer. March 2014; Tampa, FL, USA 2014
54. P.L. Martin-Hirsch, R.J. Lilford, and G.J. Jarvis Adjuvant progestagen therapy for the treatment of endometrial cance: review and meta-analyses of published randomised controlled trials Eur J Obstet Gynecol Reprod Biol 65 2 1996 201 207
55. COSA-NZ-UK Endometrial Cancer Study Groups Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer Int J Gynecol Cancer 8 5 1998 387 391
56. M. Takano, H. Ochi, Y. Takei, M. Miyamoto, Y. Hasumi, Y. Kaneta, and et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer 109 7 2013 1760 1765
57. E. Sartori, A. Gadducci, F. Landoni, A. Lissoni, T. Maggino, P. Zola, and et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy Int J Gynecol Cancer 11 6 2001 430 437
58. A. Mariani, M.J. Webb, G.L. Keeney, G. Calori, and K.C. Podratz Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement Gynecol Oncol 83 1 2001 72 80
59. J.D. Wright, J. Fiorelli, A.L. Kansler, W.M. Burke, P.B. Schiff, C.J. Cohen, and et al. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation Am J Obstet Gynecol 200 4 2009 419.e1 419.e7
60. P.J. Disaia Predicting parametrial involvement in endometrial cancer: is this the end for radical hysterectomies in stage II endometrial cancers? Obstet Gynecol 116 5 2010 1016 1017
61. A.J. Mundt, R. McBride, J. Rotmensch, S.E. Waggoner, S.D. Yamada, and P.P. Connell Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy Int J Radiat Oncol Biol Phys 50 5 2001 1145 1153
62. A.H. Klopp, A. Jhingran, L. Ramondetta, K. Lu, D.M. Gershenson, and P.J. Eifel Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation Gynecol Oncol 115 1 2009 6 11
63. K. Galaal, M. Al Moundhri, A. Bryant, A.D. Lopes, and T.A. Lawrie Adjuvant chemotherapy for advanced endometrial cancer Cochrane Database Syst Rev 5 2014 CD010681
64. M.E. Randall, N.M. Spirtos, and P. Dvoretsky Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122 J Natl Cancer Inst Monogr 19 1995 13 15
65. H.D. Homesley, V. Filiaci, S.K. Gibbons, H.J. Long, D. Cella, N.M. Spirtos, and et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study Gynecol Oncol 112 3 2009 543 552
66. J.A. Vargo, M.M. Boisen, J.T. Comerci, H. Kim, C.J. Houser, P. Sukumvanich, and et al. Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria Gynecol Oncol 135 2 2014 190 195
67. J.N. Barlin, I. Puri, and R.E. Bristow Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis Gynecol Oncol 118 1 2010 14 18
68. I. Vandenput, B. Van Calster, A. Capoen, K. Leunen, P. Berteloot, P. Neven, and et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer 101 2 2009 244 249
69. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G.C. Reid, A.R. Munkarah, and et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study J Clin Oncol 22 11 2004 2159 2166
70. F.H. van Wijk, M.S. Aapro, G. Bolis, B. Chevallier, M.E. van der Burg, A. Poveda, and et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group Ann Oncol 14 3 2003 441 448
71. J.T. Thigpen, M.F. Brady, H.D. Homesley, J. Malfetano, B. DuBeshter, R.A. Burger, and et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma. A Gynecol Oncol group study J Clin Oncol 22 19 2004 3902 3908
72. T. Akram, P. Maseelall, and J. Fanning Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer Am J Obstet Gynecol 192 5 2005 1365 1367
73. P.J. Hoskins, K.D. Swenerton, J.A. Pike, F. Wong, P. Lim, C. Acquino-Parsons, and et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study J Clin Oncol 19 20 2001 4048 4053
74. D. Miller, V. Filiaci, G. Fleming, R. Mannel, D. Cohn, T. Matsumoto, and et al. Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study Gynecol Oncol 125 3 2012 771
75. B. Sorbe, H. Andersson, K. Boman, P. Rosenberg, and M. Kalling Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up Int J Gynecol Cancer 18 4 2008 803 808
76. F. Zagouri, G. Bozas, E. Kafantari, M. Tsiatas, N. Nikitas, M.A. Dimopoulos, and et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int 2010 2010 749579
77. C.R. Calabrese, R. Almassy, S. Barton, M.A. Batey, A.H. Calvert, S. Canan-Koch, and et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361 J Natl Cancer Inst 96 1 2004 56 67
78. N. Bansal, V. Yendluri, and R.M. Wenham The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies Cancer Control 16 1 2009 8 13
79. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, D.M. Provencher, and et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer. A trial of the NCIC Clinical Trials Group J Clin Oncol 29 24 2011 3278 3285
80. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, R.R. Broaddus, and et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 23 2010 5415 5419
81. J. Folkman What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1 1990 4 6
82. T. Kaku, T. Kamura, N. Kinukawa, H. Kobayashi, K. Sakai, N. Tsuruchi, and et al. Angiogenesis in endometrial carcinoma Cancer 80 4 1997 741 747
83. D.W. Leung, G. Cachianes, W.J. Kuang, D.V. Goeddel, and N. Ferrara Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 4935 1989 1306 1309
84. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.F. Dvorak Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 219 4587 1983 983 985
85. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 6 2003 669 676
86. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J 13 1 1999 9 22
87. H. Zeng, H.F. Dvorak, and D. Mukhopadhyay Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways J Biol Chem 276 29 2001 26969 26979
88. C. Aghajanian, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, P.G. Rose, and et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study J Clin Oncol 29 16 2011 2259 2265
89. F. Simpkins, R. Drake, P.F. Escobar, B. Nutter, N. Rasool, and P.G. Rose A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) Gynecol Oncol 136 2 2015 240 245
90. E.A. Alvarez, W.E. Brady, J.L. Walker, J. Rotmensch, X.C. Zhou, J.E. Kendrick, and et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 129 1 2013 22 27
91. K.K. Leslie, M.W. Sill, E. Fischer, K.M. Darcy, R.S. Mannel, K.S. Tewari, and et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study Gynecol Oncol 129 3 2013 486 494
92. B.M. Slomovitz, Y. Jiang, M.S. Yates, P.T. Soliman, T. Johnston, M. Nowakowski, and et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma J Clin Oncol 33 8 2015 930 936
93. C. Morrison, V. Zanagnolo, N. Ramirez, D.E. Cohn, N. Kelbick, L. Copeland, and et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients J Clin Oncol 24 15 2006 2376 2385
94. G.F. Fleming, M.W. Sill, K.M. Darcy, D.S. McMeekin, J.T. Thigpen, L.M. Adler, and et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 1 2010 15 20
95. I. Podzielinski, M.E. Randall, P.J. Breheny, P.F. Escobar, D.E. Cohn, A.M. Quick, and et al. Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma Gynecol Oncol 124 1 2012 36 41
96. M. Koskas, J. Uzan, D. Luton, R. Rouzier, and E. Darai Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis Fertil Steril 101 3 2014 785 794
97. M. Koskas, S. Bendifallah, D. Luton, E. Darai, and R. Rouzier Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery Fertil Steril 98 5 2012 1229 1235
98. J.R. Allsop, J. Preston, and S. Crocker Is there any value in the long-term follow up of women treated for endometrial cancer? BJOG 104 1 1997 122
99. H.B. Salvesen, L.A. Akslen, T. Iversen, and O.E. Iversen Recurrence of endometrial carcinoma and the value of routine follow up BJOG 104 11 1997 1302 1307
100. O.O. Agboola, E. Grunfeld, D. Coyle, and G.A. Perry Costs and benefits of routine follow-up after curative treatment for endometrial cancer CMAJ 157 7 1997 879 886
101. A.G. Shumsky, G.C. Stuart, P.M. Brasher, J.G. Nation, D.I. Robertson, and S. Sangkarat An evaluation of routine follow-up of patients treated for endometrial carcinoma Gynecol Oncol 55 2 1994 229 233
102. I. Ackerman, S. Malone, G. Thomas, E. Franssen, J. Balogh, and A. Dembo Endometrial carcinoma-relative effectiveness of adjuvant irradiation vs therapy reserved for relapse Gynecol Oncol 60 2 1996 177 183
103. M. Fung-Kee-Fung, J. Dodge, L. Elit, H. Lukka, A. Chambers, and T. Oliver Follow-up after primary therapy for endometrial cancer. A systematic review Gynecol Oncol 101 3 2006 520 529
104. F.M. Kew, A.P. Roberts, and D.J. Cruickshank The role of routine follow-up after gynecological malignancy Int J Gynecol Cancer 15 3 2005 413 419
105. R. Salani, C.I. Nagel, E. Drennen, and R.E. Bristow Recurrence patterns and surveillance for patients with early stage endometrial cancer Gynecol Oncol 123 2 2011 205 207
106. E. Sartori, B. Pasinetti, L. Carrara, A. Gambino, F. Odicino, and S. Pecorelli Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients Gynecol Oncol 107 1 Suppl 1 2007 S241 S247
107. A. Berchuck, C. Anspach, A.C. Evans, J.T. Soper, G.C. Rodriguez, R. Dodge, and et al. Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma Gynecol Oncol 59 1 1995 20 24
108. H. Hampel, W. Frankel, J. Panescu, J. Lockman, K. Sotamaa, D. Fix, and et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients Cancer Res 66 15 2006 7810 7817
109. J. Moline, and C. Eng Equality in lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard? J Clin Oncol 32 21 2014 2277
110. L.M. Wiltink, R.A. Nout, M. Fiocco, E. Meershoek-Klein Kranenbarg, I.M. Jurgenliemk-Schulz, J.J. Jobsen, and et al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 Trials J Clin Oncol 33 15 2015 1640 1646